Bio-Rad Laboratories, Inc. (BIO)
| Market Cap | 10.26B +22.7% |
| Revenue (ttm) | 2.59B +1.4% |
| Net Income | 1.02B |
| EPS | 37.95 |
| Shares Out | 26.89M |
| PE Ratio | 10.05 |
| Forward PE | 35.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 273,160 |
| Open | 364.45 |
| Previous Close | 369.00 |
| Day's Range | 363.59 - 384.62 |
| 52-Week Range | 236.73 - 396.23 |
| Beta | 1.06 |
| Analysts | Hold |
| Price Target | 356.67 (-6.53%) |
| Earnings Date | Nov 4, 2026 |
About BIO
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory e... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for BIO stock is "Hold." The 12-month stock price target is $356.67, which is a decrease of -6.53% from the latest price.
News
Bio-Rad price target raised to $440 from $390 at RBC Capital
RBC Capital raised the firm’s price target on Bio-Rad (BIO) to $440 from $390 and keeps an Outperform rating on the shares. The firm notes that the company’s Q3 results…
Bio-Rad Laboratories Earnings Call Transcript: Q3 2026
Q3 revenue edged higher, with non-GAAP margins improving and clinical diagnostics returning to growth. Guidance was reaffirmed, while 2027 plans target positive growth amid continued funding, pricing, and logistics headwinds.
Bio-Rad Laboratories Earnings release: Q3 2026
Bio-Rad Laboratories released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Bio-Rad Laboratories Slides: Q3 2026
Bio-Rad Laboratories has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
Bio-Rad Laboratories Quarterly report: Q3 2026
Bio-Rad Laboratories has published its Q3 2026 quarterly earnings report on November 4, 2026.
Bio-Rad reports Q3 adjusted EPS $2.65, consensus $2.23
Reports Q3 revenue $656.4M, consensus $649.95M. Norman Schwartz, Bio-Rad’s (BIO) Chief Executive Officer, stated: “Our third-quarter results reflect the steady progress we have been driving. We return...
Bio-Rad Reports Third-Quarter 2026 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...
Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financia...
Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t...
Bio-Rad Laboratories Transcript: Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
A new executive team is driving a multi-year transformation focused on operational excellence, portfolio differentiation, and disciplined M&A. Droplet Digital PCR remains a core growth driver, with recent acquisitions expanding market reach. The company is navigating challenging end markets through strategic pivots and ongoing organizational change.
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financia...
Bio-Rad Laboratories Transcript: Wells Fargo 21st Annual Healthcare Conference
Q2 saw sequential improvement, driven by digital PCR growth and stable diagnostics, with APAC strength and improving A&G sentiment. Forward guidance expects a Q4 ramp, supported by quality controls and blood typing. R&D reprioritization, AI integration, and restructuring aim to drive margin expansion and long-term growth.
Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financia...
Bio-Rad price target raised to $390 from $370 at RBC Capital
RBC Capital raised the firm’s price target on Bio-Rad (BIO) to $390 from $370 and keeps an Outperform rating on the shares.
Bio-Rad price target raised to $370 from $320 at RBC Capital
RBC Capital raised the firm’s price target on Bio-Rad (BIO) to $370 from $320 and keeps an Outperform rating on the shares. Bio-Rad’s Q2 results and restructuring plans support expectations…
Bio-Rad price target raised to $330 from $300 at Citi
Citi raised the firm’s price target on Bio-Rad (BIO) to $330 from $300 and keeps a Neutral rating on the shares.
Bio-Rad Laboratories Earnings Call Transcript: Q2 2026
Q2 2026 revenue was flat year-over-year but up 10% sequentially, with clinical diagnostics returning to growth and digital PCR showing strong instrument sales. The company reaffirmed full-year guidance, announced a restructuring for long-term savings, and continues to face headwinds in China and academic markets.
Bio-Rad Laboratories Earnings release: Q2 2026
Bio-Rad Laboratories released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Bio-Rad Laboratories Quarterly report: Q2 2026
Bio-Rad Laboratories has published its Q2 2026 quarterly earnings report on August 4, 2026.
Bio-Rad Laboratories Slides: Q2 2026
Bio-Rad Laboratories has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Bio-Rad inititates restructuring plan, to cut jobs
According to a regulatory filing, on July 31, 2026, Bio-Rad (BIO) Laboratories initiated a strategy-driven restructuring plan as part of our ongoing program to improve operating performance and streng...
Bio-Rad reports Q2 adjusted EPS $2.62, consensus $1.75
Reports Q2 revenue $651M, consenesus $623.99M. Norman Schwartz, Bio-Rad’s (BIO) Chairman and Chief Executive Officer, stated: “Second-quarter reported revenue was flat year-over-year, with growth in C...
Bio-Rad Reports Second-Quarter 2026 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...
Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t...
Bio-Rad slips as Sartorius weighed on by Danaher bioprocessing unit miss
Sartorius (SSSGY) shares are trading lower in Europe after earnings from competitor Danaher (DHR), including bioprocessing unit results that missed expectations. Bio-Rad Laboratories (BIO), which owns...